3.8 Article

Brain simulation augments machine-learning-based classification of dementia

Publisher

WILEY
DOI: 10.1002/trc2.12303

Keywords

Alzheimer's disease; machine learning; multi-scale brain simulation; positron emission tomography; The Virtual Brain

Funding

  1. Alzheimer's Disease Neuroimaging Initiative (ADNI
  2. National Institutes of Health) [U01 AG024904]
  3. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  4. National Institute on Aging
  5. National Institute of Biomedical Imaging and Bioengineering
  6. AbbVie
  7. Alzheimer's Association
  8. Alzheimer's Drug Discovery Foundation
  9. Araclon Biotech
  10. BioClinica, Inc.
  11. Biogen
  12. Bristol-Myers SquibbCompany
  13. CereSpir, Inc.
  14. Cogstate
  15. Eisai Inc.
  16. Elan Pharmaceuticals, Inc.
  17. Eli Lilly and Company
  18. EuroImmun
  19. F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
  20. Fujirebio
  21. GE Healthcare
  22. IXICO Ltd.
  23. Janssen Alzheimer Immunotherapy Research & Development, LLC
  24. Johnson & Johnson Pharmaceutical Research & Development LLC
  25. Lumosity
  26. Lundbeck
  27. Merck Co., Inc.
  28. Meso Scale Diagnostics, LLC
  29. NeuroRx Research
  30. Neurotrack Technologies
  31. Novartis Pharmaceuticals Corporation
  32. Pfizer Inc.
  33. Piramal Imaging
  34. Servier
  35. Takeda Pharmaceutical Company
  36. Transition Therapeutics
  37. Canadian Institutes of Health Research
  38. EU [826421, 785907]
  39. ERC [945539, 683049]
  40. German Research Foundation [SFB 1436, 425899996, SFB 1315, 327654276, SFB 936, 178316478, SFB-TRR 295, 424778381, RI 2073/6-1, RI 2073/10-2, RI 2073/9-1]
  41. PHRASE Horizon EIC grant [101058240]
  42. Berlin Institute of Health & Foundation Charite, Johanna Quandt Excellence Initiative
  43. ERAPerMed PatternCog
  44. European Research Council (ERC) [683049] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

Computational brain network modeling using The Virtual Brain (TVB) simulation platform, combined with machine learning and multi-modal neuroimaging, can reveal mechanisms and improve diagnostics in Alzheimer's disease (AD). This study enhances whole-brain simulation by linking local amyloid beta (Aβ) positron emission tomography (PET) with altered excitability, and demonstrates improved classification accuracy when combining empirical neuroimaging features and simulated local field potentials (LFPs).
Introduction Computational brain network modeling using The Virtual Brain (TVB) simulation platform acts synergistically with machine learning (ML) and multi-modal neuroimaging to reveal mechanisms and improve diagnostics in Alzheimer's disease (AD). Methods We enhance large-scale whole-brain simulation in TVB with a cause-and-effect model linking local amyloid beta (A beta) positron emission tomography (PET) with altered excitability. We use PET and magnetic resonance imaging (MRI) data from 33 participants of the Alzheimer's Disease Neuroimaging Initiative (ADNI3) combined with frequency compositions of TVB-simulated local field potentials (LFP) for ML classification. Results The combination of empirical neuroimaging features and simulated LFPs significantly outperformed the classification accuracy of empirical data alone by about 10% (weighted F1-score empirical 64.34% vs. combined 74.28%). Informative features showed high biological plausibility regarding the AD-typical spatial distribution. Discussion The cause-and-effect implementation of local hyperexcitation caused by A beta can improve the ML-driven classification of AD and demonstrates TVB's ability to decode information in empirical data using connectivity-based brain simulation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available